🧬 Novartis: Kisqali shows strong effect in young breast cancer patients

$NOVN (+0.93%)

• New study data show a significantly improved efficacy of the cancer drug Kisqaliespecially in women under 40 years of age.
• The combination with endocrine therapy significantly delays the course of the disease.
• This makes Kisqali more attractive for a broader application and could against competing drugs.
• The data were presented at a leading oncology conference and could Strengthen Novartis' market position.

Source: https://de.investing.com/news/economy-news/novartisbrustkrebsmittel-kisqali-ist-auch-bei-jungeren-patientinnen-wirksam-3019861